摘要
为观察经皮动脉灌注化疗药物及ＬＡＫ／ＩＬ－２治疗晚期贲门癌的疗效，采用经皮穿刺胃左动脉插管灌注健康人外周血ＬＡＫ细胞１×１０８／Ｌ及ＩＬ－２３０万Ｕ，化疗药物为表阿霉素３０ｍｇ、卡铂３００ｍｇ、长春地辛（西艾克）４ｍｇ或５－Ｆｕ１０００ｍｇ，每３周～４周一次，２次为一疗程，结果：经病理学确诊的共７８例晚期贲门癌患者经此法共介入灌注１４６次，最多者５次，最少者１次，胃部病灶ＣＲ＋ＰＲ占６１．５％，生存最长４１个月，最短４个月，中位生存期９．５个月，半年生存率为７６．９％，１年生存率为３０．８％，提示采用肿瘤供血动脉进行区域性灌注生物制剂及化疗药物，对于失去手术机会的晚期贲门癌病人不失为可供选择的有效治疗手段。
The therapeutic effect of chemotherapeutic drugs and LAK/IL Ⅱ in intrarterial therapy in the treatment of late stage cardiac cancer was obserred. We adapted percutaneous left gastric artery intervention therapy to the patients once every 3 4 weeks, with LAk cells (from healthy person)1×10 9/100 ml, IL Ⅱ 30,000 u, and chemotherapy drugs (pharmarubincin 30 mg, carboplatin 300 mg, vindesin 4 mg or 5 Fu 1000 mg). 78 cases of late stage cardiac cancer were included,ThOse achieved CR+PR accounted for 61.5%,and the medium survival time was 9.5 months and 1 year survival rate 30.8%. For patients of late stage cardiac cancer who had lost the chance of operation, intrarterial intervention therapy with biological preparations and chemotherapy drugs would be a preferable and effective way of treatment.
出处
《肿瘤研究与临床》
CAS
1998年第4期234-236,共3页
Cancer Research and Clinic
关键词
晚期
贲门癌
动脉灌注
IL-2
药物疗法
LAK
Late stage cardiac cancer Intraterial perfusion Chemotherapeutic drug LAK/IL Ⅱ
